Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 7/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 7/20 | 0.48 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CASR | P41180 | 2/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19808131 | 0.85 | PDE2A (0.50) | AKR1C3AKR1C2PTPN5CASRPDE2A | |
| SCHEMBL14054473 | 0.82 | KIF11 (0.59) | SLC1A3SLC1A2SLC1A1CYP1A2APP | |
| SCHEMBL2296728 | 0.82 | PTGDR2 (0.48) | SLC1A3SLC1A2SLC1A1CYP1A2PDE2A | |
| SCHEMBL26454256 | 0.82 | LMNA (0.37) | AKR1C3AKR1C2PTPN5LMNASLC1A3 | |
| SCHEMBL10078969 | 0.82 | NPBWR1 (0.47) | AKR1C3AKR1C2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL14666775 | 0.80 | KIF11 (0.44) | AKR1C3AKR1C2LMNASLC1A3SLC1A2 | |
| SCHEMBL14113002 | 0.80 | PPARA (0.45) | AKR1C3AKR1C2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL14087362 | 0.79 | PTPN5 (0.59) | AKR1C3AKR1C2PTPN5PDE2APSEN1 | |
| SCHEMBL16809158 | 0.78 | ESR2 (0.55) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL24910317 | 0.78 | AKR1C3 (0.54) | AKR1C3AKR1C2PTPN5CASRPSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221130-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180022695-A1 | GLUCAGON ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2018-01-25 | — | — | US | disclosed |
| US-9783494-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2017-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022695-A1 | GLUCAGON ANTAGONISTS | GLP1R, GCG, GCGR | AKR1C3 600/4885AKR1C2 483/4885PTPN5 503/4885 |
| US-10221130-B2 | Glucagon antagonists | GLP1R, GCG, GCGR | AKR1C3 729/4885AKR1C2 595/4885PTPN5 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.